Biogen Diranersen Phase 2 Alzheimer's Results
Analysis based on 7 articles · First reported May 14, 2026 · Last updated May 14, 2026
The positive Phase 2 CELIA study results for diranersen by Biogen are expected to have a significant positive impact on Biogen's stock price and market valuation, as it signals a promising new treatment for Alzheimer's disease. This development could also positively influence the broader biotechnology and pharmaceutical sectors, particularly companies involved in neurodegenerative disease research, and potentially benefit Ionis Pharmaceuticals due to its licensing agreement with Biogen.
Biogen announced compelling topline results from its Phase 2 CELIA study for diranersen (BIIB080), an investigational antisense oligonucleotide (ASO) therapy targeting tau in individuals with early Alzheimer's disease. The study demonstrated robust reductions in tau pathology and cognitive benefit across all studied doses, particularly at the lowest dose. While the study did not meet its primary endpoint for dose response, the strength of the biomarker and efficacy data has given Biogen confidence to advance diranersen to registrational development. This marks the first time a tau-directed therapy has shown both significant biomarker impact and cognitive benefit in a randomized Phase 2 study for early Alzheimer's disease. The United States — Food and Drug Administration had previously granted Fast Track designation to diranersen in 2025. Biogen obtained a worldwide, exclusive license to develop and commercialize diranersen from Ionis Pharmaceuticals in December 2019.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard